Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Anaesthesia ; 76(12): 1607-1615, 2021 12.
Article in English | MEDLINE | ID: mdl-33954980

ABSTRACT

Extended-release opioids are often prescribed to manage postoperative pain despite being difficult to titrate to analgesic requirements and their association with long-term opioid use. An Australian/New Zealand organisational position statement released in March 2018 recommended avoiding extended-release opioid prescribing for acute pain. This study aimed to evaluate the impact of this organisational position statement on extended-release opioid prescribing among surgical inpatients. Secondary objectives included predictors and clinical outcomes of prescribing extended-release opioids among surgical inpatients. We conducted a retrospective, dual centre, 11-month before-and-after study and time-series analysis by utilising electronic medical records from two teaching hospitals in Sydney, Australia. The primary outcome was the proportion of patients prescribed an extended-release opioid. For surgical patients prescribed any opioid (n = 16,284), extended-release opioid prescribing decreased after the release of the position statement (38.4% before vs. 26.6% after, p < 0.001), primarily driven by a reduction in extended-release oxycodone (31.1% before vs. 14.1% after, p < 0.001). There was a 23% immediate decline in extended-release opioid prescribing after the position statement release (p < 0.001), followed by an additional 0.2% decline per month in the following months. Multivariable regression showed that the release of the position statement was associated with a decrease in extended-release opioid prescribing (OR 0.54, 95%CI 0.50-0.58). Extended-release opioid prescribing was also associated with increased incidence of opioid-related adverse events (OR 1.52, 95%CI 1.35-1.71); length of stay (RR 1.44, 95%CI 1.39-1.51); and 28-day re-admission (OR 1.26, 95%CI 1.12-1.41). Overall, a reduction in extended-release opioid prescribing was observed in surgical inpatients following position statement release.


Subject(s)
Analgesics, Opioid/therapeutic use , Drug Prescriptions/statistics & numerical data , Pain, Postoperative/drug therapy , Adult , Aged , Analgesics, Opioid/adverse effects , Analgesics, Opioid/chemistry , Australia , Delayed-Action Preparations/adverse effects , Delayed-Action Preparations/chemistry , Hospitals, Teaching , Humans , Inpatients , Length of Stay/statistics & numerical data , Logistic Models , Male , Middle Aged , New Zealand , Odds Ratio , Opioid-Related Disorders/etiology , Patient Readmission/statistics & numerical data , Practice Guidelines as Topic , Retrospective Studies
2.
Diabet Med ; 34(3): 432-439, 2017 03.
Article in English | MEDLINE | ID: mdl-27135418

ABSTRACT

AIMS: To examine the appropriateness of medicine use and potentially high-risk prescribing before and after hospitalization for diabetes. METHODS: A retrospective cohort study of patients hospitalized for diabetes was conducted using administrative data from the Australian Government Department of Veterans' Affairs for the period between 1 January 2012 and 31 December 2012. The appropriateness of medicine use and potentially high-risk prescribing, including hyper-polypharmacy and associated treatment conflicts, were examined for the 120-day periods before and after hospitalization. RESULTS: A total of 876 patients were hospitalized for a diabetes-related complication. Of these, 25% were not dispensed an antidiabetic medicine 4 months before hospitalization and 25% had not had their HbA1c levels measured in the preceding 6 months. The use of antidiabetic medicines increased to 85% after hospitalization, with a 25.6% relative increase (95% CI 10.9-42.1) in the proportion of those dispensed insulin. The prevalence of high-risk prescribing before hospital admission was high; 70% had > 10 medicines dispensed, a third had at least one treatment conflict and half were dispensed a potentially inappropriate medicine. The use of long-acting sulphonylureas and corticosteroids had relative decreases of 46.0% (95% CI 17.0-64.9) and 29.9% (95% CI 8.8-46.0), respectively. Few changes in other high-risk prescribing patterns were observed after discharge. CONCLUSIONS: This study has identified poor medication-related care and, in particular, high-risk-prescribing in people subsequently hospitalized for diabetes. While diabetes medicine use improved after hospitalization, there was little change in potentially inappropriate medicine use, which suggests that an opportunity to improve medication use in this older vulnerable population has been missed.


Subject(s)
Aging , Diabetes Complications/therapy , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Inappropriate Prescribing/adverse effects , Administrative Claims, Healthcare , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Aged , Aged, 80 and over , Australia , Cohort Studies , Combined Modality Therapy , Diabetes Complications/drug therapy , Diabetes Complications/mortality , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/mortality , Diabetes Mellitus, Type 2/therapy , Electronic Health Records , Female , Hospital Mortality , Humans , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Insulin/therapeutic use , Male , Polypharmacy , Retrospective Studies , Sulfonylurea Compounds/adverse effects , Sulfonylurea Compounds/therapeutic use , Veterans Health
SELECTION OF CITATIONS
SEARCH DETAIL
...